BOSENTAN MONOHYDRATE
( DrugBank: Bosentan, Bosentan monohydrate / KEGG DRUG: Bosentan, Bosentan, Bosentan, Bosentan )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 2 |
| 84 | Sarcoidosis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 40 |
| 88 | Chronic thromboembolic pulmonary hypertension | 8 |
51. Scleroderma
Clinical trials : 740 / Drugs : 813 - (DrugBank : 165) / Drug target genes : 140 - Drug target pathways : 231
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
84. Sarcoidosis
Clinical trials : 196 / Drugs : 261 - (DrugBank : 78) / Drug target genes : 73 - Drug target pathways : 183
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
86. Pulmonary arterial hypertension
Clinical trials : 1,348 / Drugs : 828 - (DrugBank : 133) / Drug target genes : 82 - Drug target pathways : 197
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
88. Chronic thromboembolic pulmonary hypertension
Clinical trials : 187 / Drugs : 144 - (DrugBank : 24) / Drug target genes : 18 - Drug target pathways : 82
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|